Over the past decade, researchers have put a great amount of effort into developing suitable models for the analysis of longitudinal CD4 data and other markers of AIDS progression. These models must be general enough to allow for different patterns of change in the marker data. In this paper, we review the existing literature including our preferred models which involve mixed effects, stochastic terms and independent measurement error. Adding stochastic terms to standard mixed effects models gives an interpretable and parsimonious method for generalizing the covariance structure of the measurement error and short-term variability. We focus on univariate and bivariate models with integrated Ornstein±Uhlenbeck (IOU) stochastic terms. The IOU process allows for a range of biologically plausible derivative tracking that encompasses both random trajectory and Brownian motion behaviour. We illustrate these modelling techniques on longitudinal CD4 and viral RNA data.
Introduction
There is a considerable literature on ®nding suitable models for clinical markers of AIDS. The most widely used marker is the CD4 lymphocyte count, but more recently measures of HIV viral load (especially measures of viral RNA or DNA) have become important.
The available data on such markers are usually characterized by unequal numbers of unevenly spaced observations for each individual. The data are typically both intermittently missing and right censored and this censoring is often informative. We will treat only continuous measures; most of the available data can be regarded as such since the resolution of the recording instruments is high relative to the range of the measurements.
The data have many components of variability. Within an individual, we see measurement error, diurnal variation, short-term variability and long-term trends. In addition, the amount of short-term variability and long-term trend vary (often greatly) between individuals. Hughes et al. 1 quanti®ed within subject variability for CD4 counts. For example, in their study, measurements taken eight weeks apart typically differed by 20±30%. This re¯ects both laboratory error and short-term variation. Zeger and Diggle 2 suggested (at least for the CD4 data they considered) that the two components of variation are of similar size. Viral load data are also extremely variable: Cowles 3 reported that intra-patient standard deviations for measurements taken several days apart average 0.3 log 10 units. See also Raboud et al. 4 and Paxton et al. 5 Understanding the variability in these markers is extremely important from a practical standpoint. For example, it is important to determine a level of increase in CD4 count between measurements taken several months apart that is not likely to be due to random¯uctuation. More generally, we need methods to extract the signal from these noisy data (with informative missingness). Furthermore, understanding of the variability is also important for joint modelling of marker and survival data. As discussed in Jewell and Nielsen, 6 Jewell and Kalb¯eisch 7 and Fusaro et al., 8 effective models for the markers are necessary for accurate and ef®cient survival analysis. We will focus on models which attempt to partition the variability of the data into interpretable components. Section 2 discusses the application of mixed effects linear models to AIDS marker data. These models can be enhanced by the addition of a stochastic process term: we review such work in Section 3. Section 4 describes research extending the analysis to two or more markers. Both of these sections concentrate on models that use an integrated Ornstein±Uhlenbeck (IOU) stochastic term. This stochastic process is a generalization of random trajectories (perfect derivative tracking) and Brownian motion (no derivative tracking) that allows for intermediate amounts of derivative tracking. The concept of derivative tracking is discussed in Taylor et al. 9 A model is said to have strong derivative tracking if an individual tends to stay on the same ®xed path for an extended period of time and the future path is largely determined by the previous path. A model is said to have weak derivative tracking if the slope of an individual's path tends to be continually changing. Since biologically plausible models could fall anywhere in the range from perfect derivative tracking to no derivative tracking, it is desirable to let the data determine the degree of tracking.
The use of various models to study joint marker and survival data is discussed in Section 5. Finally, we demonstrate our preferred modelling techniques on viral RNA and CD4 data from a Veterans Administration study in Section 6.
Mixed effects models
The simplest effective models for marker data assume that an individual's observed values consist of a piecewise polynomial underlying trajectory (with random coef®cients) plus independent error, which is usually assumed to incorporate both measurement error and short-term variability. These models can be written in the general form
where Y i t ij represents the (appropriately transformed) jth (j 1Y F F F Y J i measurement made on the ith person (i 1Y F F F Y n) at time t ij Y X i t ij represent the ®xed effects, Z i t ij i the random effects and ij the error (assumed independent, but not necessarily identically distributed). The i values are assumed to be independently and identically distributed according to some distribution (usually with unknown hyperparameters). The measurements are usually transformed to make plausible an assumption of normally distributed errors. Notice that the times t ij of measurement are indexed by person to indicate that the measurement times can vary between individuals. These times might represent time since infection, time since entry into a study, time since randomization to an arm of a clinical trial, or calendar date. Each group of J i measurements on an individual i has dispersion matrix varY i Z i R i Z H i AE i , where R i var i and AE i var i X Typically each of these matrices would be parametrized by a small number of unknown parameters which are common to all individuals. As a simple example, for the model
where a i Y b i are distributed as a bivariate normal and the ij are assumed to be independent and identically distributed (iid) normal random variables, there are a total of six unknown parameters in the model ± ®ve for the bivariate normal distribution and one for the measurement error variance. This type of model was popularized by Laird and Ware 10 and then applied to AIDS marker data in several papers. 11±16 DeGruttola et al. 12 used this model with one additional complexity: since the times since HIV infection are unknown, they modelled t ij c ij À ( i , where c ij is the chronological time of the measurement and ( i is the unknown calendar date of infection for the ith person. Their model also allowed for a level change in the marker value at seroconversion. They used an EM-type algorithm to ®t this model to a data set of CD4 values from 201 individuals in the San Francisco Men's Health Study (SFMHS) all of whom were HIV-positive at entry time and had a complete set of ®ve CD4 measurements. They made use of an independent estimate of infection time distribution 17 to impute the missing dates of infection.
Lange et al. 13 built on this model by assuming that the random slopes and intercept depend on covariates (age and presence or absence of herpes). A fully-Bayesian speci®cation is developed by incorporating prior information where it exists and using suitably vague priors where it does not. They also allowed for heterogeneous errors and missing data. They used the Gibbs sampler to ®t the model to data from 327 individuals in the SFMHS who had as many as eight measurements on CD4 levels (spaced about six months apart, generally). Their machinery allowed for a more general piecewise linear trajectory with random knot points, however their data were ®t best by the simple linear growth curve assumption.
Carlin 14 studied a clinical trial in 467 HIV-infected individuals with CD4 counts of below 300 (or with an AIDS diagnosis) for whom AZT was either ineffective or not tolerated. They were randomized to take either didanosine (ddI) or zalcitabine (ddC) and their CD4 counts were measured at zero, two, six, 12 and 18 months after entry. About 40% of the data were missing especially in the later visits. Clinicians expected to see a slowing in CD4 drops after two months, so a piecewise linear growth model with a change point at two months was used. Random effects for population trajectory, difference in population trajectory for ddC vs ddI and difference in population trajectory for AIDS cases versus non-AIDS cases were also included. Markov chain Monte Carlo (MCMC) methods were used to generate simulations from the posterior distribution of the parameters.
Kiuchi et al. 15 focused on the Laird±Ware model with homogeneous errors and a piecewise linear growth curve with one change point. Their model attempted to capture the hypothesized rapid decline of CD4 at a time just prior to AIDS diagnosis. Thus, each individual had their own random change point. They studied 131 of the 850 men from the New York Blood Center cohort study. These 131 men were diagnosed with AIDS sometime during the six years of the study. Each individual had between one and 17 observations of CD4 count. They ®t their model with both the EM algorithm and MCMC sampling.
Shi et al. 16 put the model in equation (2.1) into a semi-parametric framework to model the CD4 counts of 92 infants born to HIV-infected mothers in Los Angeles. They modelled both the ®xed and random effects parts of the model with cubic B-splines
where Bt is a cubic B-spline basis of dimension K evaluated at time t and Ct is a transformation of this basis of reduced dimension LX Cross-validation was used to choose the number of knots for the ®xed and random effects portions of the model. They found K between ®ve and seven and L of two or three to be appropriate for ®tting the data. Given K and L, the model is a mixed effects model as in equation (2.1).
Stochastic modelling
Diggle 18 suggested the addition of a stochastic process term such as Brownian motion (BM) to each individual's model equation as a general approach for modelling longitudinal data. A general form of such a model can be written as
where W i t ij is the value of a mean zero stochastic process at time t ij and Y i t ij is the observed data or some transformation of it. We usually assume that the process is Gaussian, but not necessarily stationary. This model partitions the observations into four parts. X i represents the mean pattern for the population. Z i i gives an individual level deterministic model of change (for a given i ). W i gives a (usually continuous) stochastic variation about this deterministic path. The inclusion of W is conceptually important, because without W we would be assuming that an individual's path, over a possibly long time interval, would be described by a simple curve determined by a small number of parameters. Finally, the ij are independent measurement errors (which are indistinguishable from very short time-scale biological variation). It is important to have these independent errors in the model to capture the fact that two measurements taken a short time apart are not necessarily similar. The covariance structure of the J i measurements on the ith individual can be written as varY
where M i varW i X These three components of variance provide a very rich class of models. It is therefore quite important to use parsimonious parametrizations. For example, Z i i may just represent a random intercept. A large amount of data may be required to be able to allocate the variability and heterogeneity to the three components since, in some sense, the three terms are all competing for this variability. One technique to avoid these identi®ability problems might be to use available prior information on the size of variance components.
There are several speci®c applications of these models to AIDS data. 2, 9, 19±25 Berman 19 proposed modelling natural log of CD4 by a stationary Gaussian process plus unknown negative drift. This model has the form
This model is ®t to a data set of CD4 counts from intravenous drug users in New York city. Kanazawa 20 allowed the Gaussian process to be nonstationary; he modelled log CD4 as an unknown negative drift plus BM. This is the same model as in equation (3.2) except that W is restricted to be a Brownian motion. Galai et al. 21 proposed a stochastic model with damped exponential correlations. Speci®cally, they used
Special cases of this model include an AR(1) stochastic term 1 and constant autocorrelation 0X They ®t this model (using a piecewise linear mean structure) to marker measurements on 328 seroconverters in the Multicenter AIDS Cohort Study (MACS). They looked at univariate models for CD4 (natural scale), log of 2 -microglobulin and log of neopterin. We note that for all three of these papers, the model does not contain an independent measurement error term. Zeger and Diggle 2 included a term for a smooth trend function (which is estimated through locally adaptive kernel smoothing methods ± this smoothing estimate was shown to be nearly equivalent to a spline estimate by Silverman 26 ). This smooth curve is combined with a ®xed effect term and a stationary Gaussian process term
They used the covariance function covWsY Ws u ' 2 w f! 1 À !expÀug The model was ®t to square roots of CD4 counts from the seroconverters in the MACS study (369 individuals at the time this paper was written).
Vittinghoff et al. 22 also used local linear smoothing methods in a model with a stochastic term component to look at square roots of CD4 counts in the SFMHS. They introduced two different methods for estimating the underlying curve patterns.
Taylor et al. 9 modelled the fourth root of CD4 counts using an IOU process. An IOU process is a zero-mean nonstationary Gaussian process with covariance function covWsY Ws u ' 2 w 2! 3 2!s e À!su e À!s À 1 À e À!u h i
The two parameters ' 2 w and ! control the variability of the process and the degree to which the derivatives`track'. A small ! and ' 2 w give a process which tends to continue on similar trajectories for long periods of time. Conversely, a large ! and ' 2 w result in a process which has very little`memory' for past derivatives. By letting ! 3 I while holding ' 2 w a! 2 equal to a constant (v, say) scaled Brownian motion is obtained, i.e. covWsY Ws u vsX
The IOU process was put into a model along with random linear trend and measurement error
where a i Y b i has a bivariate normal distribution and the ij were assumed to be iid normal with common variance ' 2 e and Y i t ij is the fourth root of the CD4 count at time t ij X This model, therefore, has eight unknown parameters ± ®ve for the distribution of aY bY two for the covariance structure of W and one for the measurement error variance. In practice, there was confounding between the random slope and the stochastic process parameters. A slightly reduced model with a nonrandom slope, i.e.
was used instead ± this reduced model has only six parameters. This model covers a wide range of biologically plausible behaviour. It was found that the same model but with W a scaled Brownian motion process ®t almost equally as well. In other words, a model with no derivative tracking was found to be consistent with the CD4 count data in this study.
Wang and Taylor 23 analysed data from an AIDS clinical trial with a model of the form
where " g t is a smooth mean curve for group g. In particular, each " g was taken to be a cubic polynomial spline. To avoid over®tting, the splines were ®t through penalized likelihood, with roughness penalty ! (which is selected through cross-validation techniques). For a given value of !Y though, this can be put under the framework of equation (3.1) if prior information is allowed on the ®xed effect parameters in that model. Several choices for Wt were considered including a generalized AR(1) type process and a random effects model. The model was applied to data from AIDS Clinical Trial Group 016 (ACTG 016) which followed 61 HIV-positive patients, 34 randomized to AZT and 27 to placebo.
LaValley and DeGruttola 25 combined ideas from Taylor et al., 9 and Tsiatis et al. 27 in the analysis of a three-arm AIDS clinical trial, with particular focus on evaluating whether CD4 is a good surrogate endpoint.
Taylor and Law 24 compared the importance of the particular choice of covariance structure for predicting future CD4 values. The main ®nding of this paper was that the choice of covariance structure is important for individual level predictions. The IOU and Brownian motion models appeared not only to give a better ®t (based on likelihood) to CD4 counts from the MACS study, but also to be more ef®cient and accurate in making future predictions (based on the MACS data and a simulation study). Random effects models in the cases examined, appeared to ®t the MACS data reasonably well, but did not perform as well in predictions for individuals. CD4 counts were transformed by square root, cube root and fourth root with no difference in results.
Bivariate marker models
Sy et al. 28 extended the model in Taylor et al., 9 (Section 3) to joint modelling of both CD4 and 2 -microglobulin measurements using a bivariate IOU process (see Jones, 29 for example). Let B and C be k Â k real matrices subject to certain conditions including C symmetric (see Cox and Miller, 30 p 226) . The k-variate IOU process has covariance function covsY s u e f H s À s À f H sf HÀP g gf ÀP e fsu À e fu À fs 4X1
for s and u non-negative. If the eigenvalues of B tend to minus in®nity while holding CB À1 constant, we obtain CovWsY Ws u VsY where V is positive-de®nite and symmetric. For k 2, this is the covariance function of a bivariate scaled Brownian motion process with variances v 11 and v 22 and inter-variable covariance v 12 X The bivariate version of the IOU process has four parameters for B and three for C (since it is symmetric), for a total of seven parameters; the bivariate Brownian motion process has only three parameters for VX The off-diagonal elements of B have an interesting possible interpretation. If, for example, B is lower triangular, then a change in the derivative of the ®rst process is affected by the derivatives of both processes. However, a change in the derivative of the second process is only affected by the derivative of the second process. That is, the model allows for asymmetry in how Y 1 and Y 2 in¯uence each other. The full model considered was
i is a bivariate IOU process, and 1 i Y 2 i are independent and normally distributed with variances ' 2 e1 and ' 2 e2 , respectively. This model was ®t to data from the Los Angeles portion of the MACS study. CD4 was transformed by a fourth root and 2 -microglobulin by logarithm. As in the univariate case, it was dif®cult to differentiate between the stochastic process parameters and the random slopes. Therefore, b and d were constrained to be ®xed effects in conjunction with the IOU process (or the Brownian motion special case); random b i and d i were still used for the random effects model.
Joint models for markers and survival
More recently, focus has centred around joint modelling of marker and survival data. Intuitively, the longitudinal pattern of the marker data should give more information about survival than simple ®xed covariate models.
Jewell and Kalb¯eisch 7 stressed the importance of joint modelling of marker and survival data for AIDS research. They discussed informative censoring and gave a framework for doing analysis.
Tsiatis et al. 27 developed a joint model for CD4 marker data and time to death for 281 patients in a clinical trial of AZT. The model for logarithm of CD4 was random piecewise linear (with a knot to allow for AZT effect). The parameters in this model were put into a proportional hazards model. Their results suggested that CD4 is not entirely satisfactory as a surrogate marker for clinical endpoints such as progression to AIDS or death.
DeGruttola and Tu 31 studied 511 patients enrolled between 1986 and 1987 in protocol 002 of the ACTG. Four-hundred-and-twenty-one of these patients had died by 1990. They used a random piecewise quadratic model for logarithm of CD4 together with an accelerated failure time model (AFT) for survival times. Faucett and Thomas 32 looked at 109 HIV-positive individuals who had contracted the virus through blood transfusion (and for whom the exact date of infection was known). Log CD4 and square root CD4 were both modelled by random linear trajectories. The parameters from this model were incorporated into a proportional hazards model for time to AIDS progression. Their model was fully Bayesian and was ®t using Gibbs sampling.
Pawitan and Self 33 combined a random piecewise linear marker model with a Weibull survival model to study time to AIDS progression for 159 patients in the Toronto AIDS cohort study. They considered both log of CD4 and log of the CD4-to-CD8 ratio. They found that the latter marker was a better predictor of time to AIDS.
Cowles 3 used a random effects model for logarithm of viral RNA measurements to look at the 37 patients in ACTG 116B/117 who received continuing AZT treatment. The parameters for the marker model were put into an accelerated failure time model with time varying covariates to look at time to AIDS progression. A fully Bayesian model was speci®ed and ®t using MCMC methods.
Doksum and Normand 34 combined stochastic process models (similar to those of Berman 19, 35 as discussed in Section 3) with survival data from the SFMHS. This work built on the ideas in Doksum. 36 
Analysis of viral load data
We illustrate the methods described in this paper using some data from an AIDS clinical trial. The trial we consider is Veterans Administration Cooperative Group trial 298 of early versus late AZT. 37, 38 The stochastic longitudinal models described in Sections 3 and 4 will be ®t to the CD4 and viral load observations in the late treatment arm. We consider the three-year follow-up period prior to the termination of the double-blinded portion of the study, and we exclude observations from patients after they switched to AZT. We further restrict analysis to the subset of patients with at least one viral load measurement and exclude the baseline data (the patients were enrolled into the study subject to a certain range of CD4 count ± thus, the variance at baseline was much smaller than the model assumes). This restricted data set is essentially an untreated cohort of 141 HIV infected subjects. The protocol called for measurement at one, two, four, eight, 12, 16, 20 and 24 months after randomization, but most subjects had either fewer or more measurements than this. Many subjects had an additional viral load measurement at seven days past randomization which is included in the analysis. The mean follow-up time was 15.4 months. The total number of CD4 count measurements was 817. Ninety per cent of the patients had between one and 10 CD4 counts. The total number of viral load measurements was 659. The number of viral loads measurements on an individual was between one and 12 for 90% of the patients.
We ®rst ®t a univariate model to the base 10 logarithm of the viral load data (denoted Y H , for number of copies of HIV) with bivariate normal random effects for the intercept and slope, i.e.
where the measurement error is assumed iid normal with variance ' 2 H X We refer to this model as REaY b MEX We next ®t the same model with the addition of a scaled Brownian motion term. This term is parameterized by v H : the variance of the stochastic process at time 1. As explained in Section 3, we found that we needed to restrict the slope parameter to be a ®xed effect giving us a total of ®ve parameters. This model will be denoted REa FEb BM ME. We also ®t an IOU model (which has one more parameter than the Brownian motion model), but it is not shown as the parameter estimates converged towards the Brownian motion estimates, with no signi®cant improvement in the log-likelihood. The results for ®tting the two univariate models to the viral load data are given in Table 1 .
The log likelihood for the Brownian motion model is a bit higher. The estimates of the population intercepts and slope are very similar for both models, as we had observed before with CD4 data. 9 The models indicate a baseline level of viral load of around 4X05 base-10 logs, or about 11 000 copies. The slope coef®cient indicates a slow increase of around 0.05 per year (increase of about 10% in natural units), although this estimate is not signi®cantly different from zero for either model. In comparison, this effect is much smaller than the observed effect of AZT or other current treatments. Model 2 gives us plausible parameter estimates, one less parameter and a greater loglikelihood. Based on our previous work, we feel that this model quite likely will give more accurate predictions of future marker values on an individual. 24 Furthermore, the IOU model (which is capable of exhibiting either random trajectory or Brownian motion-type behaviour) suggests that no derivative tracking is most in agreement with the data.
Next, we combine the viral load data with the CD4 data. The CD4 counts are transformed by fourth roots 9 and denoted as Y C X We consider a variety of random effects and stochastic models for the bivariate data. The random effects models have the form
The ®rst model assumes a general four-dimensional normal distribution for
This model therefore has 16 parameters: 14 for the multivariate normal and two for the measurement error variances. We will abuse the shorthand introduced in the univariate model and refer to this model as REaY bY cY d MEX This is model 1a in Tables 2 and 3 . Model 1b assumes that a i Y b i and c i Y d i have independent bivariate normal distributions. This model has 12 parameters ± we will write it as REaY b REcY d MEX Next, we looked at adding a stochastic term to the bivariate random effects models. As for the univariate models, we need to restrict the slope parameters to be ®xed effects, with the intercepts remaining as random effect terms, possibly correlated. We considered three different models with Brownian motion. Model 2a adds a bivariate Brownian motion term for a total of 12 parameters. The shorthand for this model is REaY c FEbY d BVBM MEX Model 2b assumes independent Brownian motion terms (IBM) and has 11 parameters. Finally, model 2c assumes completely independent univariate models, REa REc FEbY d IBM MEY for 10 parameters. We also ®t several types of bivariate IOU models by placing different restrictions on the covariance parameters in the B matrix (see equation (4.1)). However, we found that the restricted models either ®t poorly or else converged towards the bivariate Brownian motion model. The unrestricted bivariate IOU model (which has 16 parameters) ®t only slightly better than the bivariate Brownian motion, had very large negative eigenvalues for the B matrix, and had similar parameter estimates to the bivariate Brownian motion. Therefore, we restrict attention in this paper to the Brownian motion models since the data seem to support very little derivative tracking. Tables 2 and 3 show the results of ®tting these models to the viral load and CD4 counts. The Brownian motion models ®t better as measured by the likelihood than their random effects counterparts (i.e. model 2a, bivariate Brownian motion, ®t better than model 1a, bivariate random effects; model 2c, independent Brownian motions, ®t better than model 1b, independent random effects), and, in each case, have fewer parameters. Within the Brownian motion models, the bivariate model ®ts signi®cantly better than either of the independent stochastic models. All the models estimate a starting level for fourth root of CD4 of around 4X3 (around 350 on the natural scale) with a decrease of À0X25 per year. We remark again, that this is small compared to the immediate increase seen after treatment by AZT or other drug regimens. For random effects model 1a, the intervariable covariance parameters in Table 3 have sensible interpretations: higher initial CD4 counts are associated with lower initial viral loads, as re¯ected in a negative correlation ' ac ; steeper CD4 decreases are associated with steeper viral load increases, so ' bd is negative. For the cross-parameter covariances, steeper CD4 declines tend to be seen in patients with high initial viral load (' ad is negative), and higher initial CD4 levels are associated with faster viral load increases (' bc is positive). This last observation probably re¯ects the fact that the virus needs CD4 cells to replicate.
For the Brownian motion models, Table 3 lists the elements of V ± the dispersion matrix for the bivariate Brownian motion process as described in Section 4. For model 2a, we observe that the off-diagonal element v HYC À0X09X This translates into a correlation of À0X09a 0X34 p 0X06 p À0X63 between the two components of the stochastic process at a given time. (For two different times, this correlation is weighted by the square root of the ratio of the earlier to the later time.) The two stochastic process terms seem to have substantial negative correlation which explains why models 2b and 2c (where the off-diagonal is constrained to be zero) do not ®t nearly as well.
One of the more informative ways to compare these models is through the predictions they make. Consider an individual with a viral load of 4X0 logs at one month (the median value at that time in the data set). Figure 1(a) shows for the bivariate Brownian motion model (model 2a) the prediction of viral load out to 12 months for this individual conditional on different levels of CD4 at one month. That is
The top line is for a transformed CD4 count equal to 3X9 (a count of 231 on the natural scale), the middle line is the prediction for Y C equal to 4X3, and the bottom line is for Y C of 4X7 (these correspond to 345 and 488, respectively on the natural scale). These three CD4 values were chosen to be the ®fth, 50th and 95th percentiles of the values in the data set at one month. Figure 1(b) shows the same plot for the random effects model (model 1a). Notice that the positive covariance ' bc causes the slope of the outer lines to`pinch' in towards the middle line in Figure 1(b) . On the other hand, the Brownian motion model predicts the same slope for all individuals. Also it is worth noting that the pointwise prediction standard errors for all these lines are around 0X6 log units which is larger than the range of the vertical axis ± the difference in predictions is small compared to the standard deviation at baseline. Here, we see for the random effects model, that the negative ' ad causes the upper and lower lines to diverge from the middle line.
These predictions show graphically the extent to which the processes are linked, and indicate that the joint modelling is de®nitely worth the effort. Separate models would generate identical prediction curves, and this does not seem clinically plausible.
Discussion
We have seen that the class of models discussed in Sections 3 and 4 is a general class which includes the simple random effects model as a special case. In general, Diggle 18 recommends including a stochastic process term in longitudinal modelling. The resulting class of models is much richer and yet retains intuitive interpretability of its parameters. For the VA data set in Section 6, the model that ®t best used random intercept, Brownian motion and independent measurement error. We attempted to ®t a generalization of this model using IOU processes, but identi®ability of the parameters was dif®cult. However, the highest likelihoods occurred at parameter values consistent with the Brownian motion solution. Certainly, this data set seems to support only a very limited amount of derivative tracking in individual marker processes. Based on this and also the likelihood values and parsimony considerations, we prefer the Brownian motion model 2a for this data set.
One solution to the identi®ability problem for the IOU models might be to use a Bayesian approach with informative prior distributions on some of the variance components. A Bayesian treatment makes particular sense in this setting as there is a fair amount of prior information on the size of these components. Inference would be done via MCMC simulations from the posterior distribution of the parameters.
Another direction for generalizing the covariance structures, might be antedependence models (see, for example, Zimmerman and Nun Äez-Anton 39 ). These models also have interpretable covariance parameters, and the IOU and Brownian motion models can be seen as special cases. Over-parametrization will certainly be an important issue here, and we would most likely need to use prior information in our model. 
